Replies to post #289420 on Bioelectronics Corp (BIEL)

[GetSeriousOK]

1. How many years before RecoveryRx gets FDA clearance for wound healing?
2. How will this company survive until then?

1. How long: minimum 1.5 years, maximum who knows.

2. How to survive: they can increase the A/S (again) or borrow money from loan sharks (again). 2022 is going to be a tough year. They spent all their cash by 2021 year end. They will probably do both: (a) increase the A/S and (b)borrow money:

2.a. Increasing the A/S: Even if KW and Staelin don't convert their notes for a couple more years, the other note holders have been converting, and the company only has 300 million shares left to issue. That's not enough.

2.b. Loan sharks! The death knell of every developmental biotech. BIEL managed to avoid this for years, but in 2021 they started the death cycle.

2.c. Another option: sell enough product to make a profit and fund operations. Their plan for this:

2.c.i. Sit on their hands and hope the OEM Partners find a way to turn things around. The OEM Partners produced DISMAL results in Q4, showing a trend of decreasing revenues. How will they change that? WILL they change that?

2.c.ii. Sell RecoveryRx even though it's not FDA cleared for wound healing. How many doctors will prescribe the ActiPatch for pain alone? They've had this option available to them for years, but they haven't done it. Why would they suddenly start in 2022? Because some sales reps ask them to? Doctors love being told what to do by sales reps.

[Patient Invester]

Yup another Biel share price Womp Womp Womp